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ZINK(II) FEROSENILTIOSEMIKARBAZON KOMPLEKS: STRUKTUR, 
ELEKTROKIMIA, PENGIKATAN DNA DAN AKTIVITI NUKLEASA 
 
 
ABSTRAK 
Empat zink kompleks yang berformula Zn{(η5-C5H5)Fe(η
5
-
C5H4)C(H)=NN=C(S)NH2}2 (V), Zn{(η
5
-C5H5)Fe(η
5
-C5H4)C(H)=NN=C(S)N(H) 
CH3}2∙CH3OH (VI), Zn{(η
5
-C5H5)Fe(η
5
-C5H4)C(H)=NN=C(S)N(H)C2H5}2 (VII), 
Zn{(η5-C5H5)Fe(η
5
-C5H4)C(H)=NN=C(S)N(H)C6H5}2∙H2O (VIII) disintesis dan 
dicirikan. Struktur kompleks ini telah ditentukan melalui analisis pembelauan sinar-
X hablur tunggal. Geometri koordinatan zink dalam kompleks ini adalah sama iaitu 
pengkoordinatan tetrahedron terherot. Kompleks ini adalah redoks aktif dengan 
memberi sambutan voltametri berkitar untuk gandingan Fe(III) − Fe(II) pada 
keupayaan hampir 0.5 V vs. Ag/AgCl. Pemalar pengikatan, Kb bagi kompleks untuk 
mengikat CT DNA adalah dalam julat 7.0 × 10
2
 hingga 4.8 × 10
3
 M
-1
. Kompleks ini 
tidak menyisip ke dalam nukliobes CT DNA sepertimana dijelaskan oleh 
pengukuran kelikatan. Mereka mempamerkan aktiviti nukleasa yang efisien tanpa 
kehadiran agen pengaktifan dengan membelah ‘supercoil’ DNA ke bentuk ‘nicked’ 
dan ‘linear’ pada kepekatan yang rendah. 
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ZINC(II) FERROCENYLTHIOSEMICARBAZONE COMPLEXES: 
STRUCTURE, 
ELECTROCHEMISTRY, DNA BINDING AND NUCLEASE ACTIVITY 
 
 
ABSTRACT 
 
Four zinc complexes of the formulae Zn{(η5-C5H5)Fe(η
5
-
C5H4)C(H)=NN=C(S)NH2}2 (V), Zn{(η
5
-C5H5)Fe(η
5
-C5H4)C(H)=NN=C(S)N(H) 
CH3}2∙CH3OH (VI), Zn{(η
5
-C5H5)Fe(η
5
-C5H4)C(H)=NN=C(S)N(H)C2H5}2 (VII), 
Zn{(η5-C5H5)Fe(η
5
-C5H4)C(H)=NN=C(S)N(H)C6H5}2∙H2O (VIII) have been 
synthesised and characterised. The structures of these complexes have been 
established by a single-crystal X-ray diffraction analysis. The coordination 
geometries of the zinc centres are identical, showing a distorted tetrahedral 
coordination. The complexes are redox active, giving a reversible cyclic 
voltammetric response of the Fe(III) − Fe(II) couple near 0.5 V vs. Ag/AgCl. The 
binding constants, Kb, of the complexes for binding with CT DNA are in the range of 
7.0 × 10
2
 to 4.8 × 10
3
 M
-1
. The complexes do not intercalate into the nucleobases of 
CT DNA as evident from viscosity measurements. They exhibit efficient nuclease 
activity in the absence of an activating agent by cleaving supercoiled DNA into 
nicked and linear forms of DNA at low concentrations. 
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1 INTRODUCTION 
      
1.1 History of Metallodrugs 
Medicinal applications of metallic elements have been practised for almost 
5000 years (Sadler & Sykes, 1991). As far back as 3000 BC, the Egyptians used 
copper to sterilise water. Gold was used in a variety of medicines in Arabia and 
China 3500 years ago. Various iron remedies were used in Egypt about 1500 BC, 
around the same time that zinc was discovered to promote the healing of wounds. In 
Renaissance era Europe, mercurous chloride was used as a diuretic and the 
nutritional essentiality of iron was discovered. It is in the last 100 years, however, 
that the medicinal activity of inorganic compounds has slowly been developed in a 
rational manner, starting in the early 1900s with K[Au(CN)2] for tuberculosis, 
antimony compounds for leishmaniasis, silver nitrate for epilepsy and various gold 
salts to treat bacterial infectious diseases (Fung & Bowen, 1996; Orvig & Abrams, 
1999; Tripathi, 2009).  
 
1.2  DNA is primary target of metal-based anti-cancer drug cisplatin 
The modern medicinal inorganic chemistry gains much attention since the 
discovery of cis-diamminedichloroplatinum(II), or cisplatin (Kelland, 2007). One of 
the most successful drugs in modern pharmacology, cisplatin, had been known since 
1845, but its antitumour was only established in 1970. Cisplatin has been used to 
treat various cancer diseases namely ovarian, cervical, head and neck, oesophageal, 
and non-small cell lung cancer (Kroep et al., 1999). Much research has been 
conducted over the 30 years following the discovery of biological activity for 
cisplatin in the attempt to elucidate its mechanism of action. Many cellular 
components including DNA, RNA, proteins, membrane phospholipids and actin 
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filaments are potential targets for cisplatin. The first clue for identifying the primary 
cellular target was the filamentous growth (Figure 1.1) of the bacteria induced by 
cisplatin, an occurrence characteristic of DNA-damaging agents such as ionizing 
radiation, UV radiation and hydroxyurea (Adler & Hardigree, 1965; Rosenkranz, 
Garro, Levy, & Carr, 1966; Witkin, 1967). Cisplatin treatment also led to lysis of 
Escherichia coli cells containing bacteriophage λ, another occurrence characteristic 
of DNA-damaging agent (Reslova, 1971). These early experiments pointed to DNA 
as an important cellular target. Lippard and co-workers have elucidated the detailed 
molecular mechanism of action, which involves covalent binding of cisplatin to 
DNA (Jamieson & Lippard, 1999).  
 
Figure 1.1: An example of filamentous growth of the bacteria induced by DNA 
damaging agents. Nuclear material appears as bright body (Adler & Hardigree, 
1965). 
 
 
1.3 Rational on designing zinc(II) ferrocenylthiosemicarbazone 
In common with many other anti-cancer drugs (Abdullah et al., 2006; Chari, 
2007; Kunwar et al., 2008; Maeda, Bharate, & Daruwalla, 2009), cisplatin induces 
normal tissue toxicity (Rowan, 2010; Srivastava et al., 1996). So, attempts are being 
made to replace this drug with non-toxic, efficacious, and target-specific 
noncovalently DNA binding anticancer drugs. Generally anticancer agents that are 
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approved for clinical use are molecules which damage DNA, block DNA synthesis 
indirectly through inhibition of nucleic acid precursor biosynthesis, or disrupt 
hormonal stimulation of cell growth (Foye, 1995). Therefore, considerable effort has 
been now focused on the development of new anticancer drugs based on transition 
metal complexes, particularly, biocompatible complexes, that bind to and cleave 
DNA under physiological conditions. Among many metal ions, zinc(II) has aroused 
our attention due a variety of factors, zinc(II) is a good Lewis acid, exchanges 
ligands rapidly and is not toxic. Both the former are requirements for a metal ion to 
be an effective hydrolytic DNA cleaver (Mancin & Tecilla, 2007). Further, zinc(II) 
has no ligand field stabilization energy and, as a consequence, it can easily adapt its 
coordination geometry to best fulfil the structural requirement of a DNA hydrolysis 
reaction (Mancin & Tecilla, 2007). In 2004, Bazzicalupi and co-workers reported a 
binuclear zinc complex [Zn2L2(OH)2]2
2+
, where L is 2,5,8,11,14-Pentaaza[15]-
[15](2,2‘)[1,15]-bipyridylophane (1) that hydrolyses the phosphate ester bond of 
bis(p-nitrophenyl)phosphate (2). They pointed out that the hydrolytic pathway is a 
concerted process (single step) where there is bridging interaction of the substrate 
with the two zinc(II) ions and nucleophilic attack of a Zn-OH function at phosphorus 
(Bazzicalupi et al., 2004).  
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In 2006, Ibrahim showed bridged μ-hydroxo zinc(II) complex 
[TtiZn(μOH)ZnTti]ClO4 (3), where Tti is hydrotris(N-xylyl-2-thioimidazolyl)borate 
(4) cleaves the P-O bond in tris(p-nitrophenyl)phosphate (5) to form a mixture of a 
monomeric phosphate diester complex and phenoxo complex (Ibrahim, 2006). 
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This is the first example of zinc-mediated hydrolysis with S3 in the coordination 
sphere capable of promoting phosphoester hydrolysis. The cleavage mechanism 
proposed by the author is shown in Scheme 1.1.  
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Scheme 1.1: The proposed mechanism for the hydrolytic cleavage of tris(p-
nitrophenyl)phosphate by [TtiZn(μOH)ZnTti]ClO4 (Ibrahim, 2006). 
Molecules that can hydrolyse phosphodiester bond are potential 
Topoisomerase inhibitors (Wang, Wang, Kingsbury, Johnson, & Hecht, 1998). 
Topoisomerase inhibitors are quoted as having a wide range of antitumour activities 
and are among the most widely used anticancer drugs clinically (Beretta, Perego, & 
Zunino, 2008; Pommier, 2006; Rothenberg, 1997; Sunami et al., 2009; Teicher, 
2008). Topoisomerase I and II are enzymes that bind to supercoiled DNA, forming a 
cleavable complex and through strand breakage, passage and re-ligation allow a wide 
variety of essential DNA metabolic reactions including replication and repair to take 
place. These enzymes are functionally related, work together and appear to be essen-
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tial to maintain cellular viability throughout the cell cycle (Rothenberg, 1997). 
Topotecan, a topoisomerase I inhibitor anti cancer agent exerts its cytotoxic effects 
by stabilizing the covalent DNA-topoisomerase I cleavable complex. When DNA 
replicates in the presence of this complex, double-strand breaks occur and the 
resulting DNA fragmentation causes cell death (Staker et al., 2002). Very recently, 
Seng and co-workers observed [Zn(3-Me-pic)2(phen)] (6) where 3-Me-pic is 3-
methyl-picolinate and phen is 1,10-phenanthroline, can inhibit the function of 
topoisomerase I. Preliminary investigation shows the complex is antiproliferative 
against MCF-7 breast cancer cells with an IC50 value of 4.8 μM (Seng et al., 2009). 
  
O
Zn
CH3O
N
N
N
N
O
CH3
O
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Metal complexes that able to cleave DNA upon photoactivation under 
physiological conditions have also received considerable attention because of their 
possible utility in highly targeted photodynamic therapeutic applications (Armitage, 
1998; Boerner & Zaleski, 2005; Bradley, Angeles-Boza, Dunbar, & Turro, 2004). 
Photodynamic therapy (PDT) has emerged as a viable alternative mode of treatment 
of cancer (Ali & van Lier, 1999; Detty, Gibson, & Wagner, 2004; Sternberg, 
Dolphin, & Brückner, 1998). PDT is based on the concept that certain therapeutic 
molecules called photosensitisers (PS) can be preferentially localised in malignant 
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tissues, and when these PSs are activated with appropriate wavelength of light, they 
pass on their excess energy to surrounding molecular oxygen, resulting in the 
generation of reactive oxygen species (ROS), such as free radicals and singlet 
oxygen (
1
O2), which are toxic to cells and tissues.
 
PDT is a non-invasive treatment 
and used for several types of cancers, and its advantage lies in the inherent dual 
selectivity. First, selectivity is achieved by a preferential localization of the 
photosensitiser in target tissue (e.g., cancer), and second, the photoirradiation and 
subsequent photodynamic action can be limited to a specific area of interest. Because 
the PS is non-toxic without light exposure, only the irradiated areas will be affected, 
even if the PS does infiltrate normal tissues. Selectivity can be further enhanced by 
combining the PS with molecular delivery systems or by conjugating PS's with 
targeting agents such as an integrin antagonist or carbohydrates, which have high 
affinity for cancer tissue (Ohulchanskyy et al., 2007). In 2002, Ishikawa and co-
workers prepared zinc complexes of cationic bis-porphyrins composed of two 
H2TMPyP meso-tetrakis(N-methyl-4-pyridyl)porphine linked with a series of 
aliphatic diamines (7) to improve less DNA photocleavage activities of the metal-
free bis-porphyrins. The poor activities seemed to be derived from their 
intermolecular aggregation properties in aqueous solution. Zinc(II) insertion into the 
metal-free cationic bis-porphyrins fully enhanced their DNA photocleavage activities 
by 3 fold (Ishikawa, Yamakawa, & Uno, 2002). In 2007, Ishikawa and co-workers 
showed that zinc(II) complexes with two TMPyP chromophores bridged by para- or 
meta-xylylenediamine (8) have potent photocleavage activity. The xylylene linkers 
and zinc ion were introduced to control interchromophoric interaction that involved 
in photosensitization of the cationic bis-porphyrins (Ishikawa, Yamakawa, & Uno, 
2007).  
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Pharmacological behaviour of a metal complex also depends on the ligand 
framework. In designing the zinc(II) complexes, we have chosen ferrocene 
conjugated to thiosemicarbazone chain. Among different organometallic systems, 
those based on ferrocene and its conjugates are of particular importance for their 
medicinal activity due to excellent stability of the ferrocene moiety in biological 
media, its lipophilicity, and its reversible redox chemistry. In addition, ferrocene 
could readily form a variety of stable conjugate species (Maity, Roy, Saha, & 
Chakravarty, 2009), for example, anticancer and antimalarial drugs, namely, 
ferrocifen (ferrocene-conjugated tamoxifen) (9) and ferroquine (ferrocene-attached 
chloroquine) (10) (Biot, 2004; Biot et al., 1997; Jaouen, Top, VessiÃ¨res, Leclercq, 
& McGlinchey, 2004). It has been reported that the cytotoxicity of tamoxifen is 
greatly enhanced due to the presence of a ferrocenyl moiety (Fc = (η5-C5H4)Fe
II(η5-
C5H5)) showing activity against oestrogen-dependent and oestrogen-independent 
breast cancer cells (Jaouen et al., 2004). In the case of chloroquine, the ferrocenyl 
moiety strongly influences the antimalarial activity (Biot, 2004; Biot et al., 1997).  
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In a latest report, when phenyl is replaced with ferrocene in the complex [Cu(Ph-
tpy)(dppz)](ClO4)2 (11), where Ph-tpy is 4′-phenyl-2,2′:6′,2′′-terpyridine and dppz is 
dipyridophenazine, the complex showed better photocytotoxicity against Hela cells 
(Maity et al., 2010). 
 
N
N
N
N
N
N
N
Cu
2+
2ClO
4
-
 
 
11 
                                      
On the other hand, thiosemicarbazone is a bio-multiutility N, S-donor ligand. 
Thiosemicarbazones can be obtained by a simple condensation reaction of an 
aldehyde or a ketone with a thiosemicarbazide, and are broadly classified as mono-
thiosemicarbazones and bis-thiosemicarbazones. The basic mono-thiosemicarbazone 
ligand has different, R
1
, R
2
, R
3
 and R
4
 substituents, and depending upon the 
substituents, various sub-classes of ligands are formed. Thiosemicabazones based on 
aldehydes (e.g., 12) have hydrogen atom as one of the substituents (R
2
) at C
2
 carbon, 
while second substituent R
1
 may be an alkyl, an aryl or a heterocyclic group. 
Similarly, substituents at N
1
 nitrogen may be both hydrogen atoms, or one hydrogen, 
and second alkyl, or aryl group, and finally N
1
 may be a part of the cyclic ring. 
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The second category, bis-thiosemicarbazones have two arms connected via a ring 
(13) or a C-C bond (14) (Lobana, Sharma, Bawa, & Khanna, 2009).  
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Thiosemicarbazones (TSC) possess a wide range of biological activity 
depending on the parent aldehyde or ketone. Brockman and co-workers first showed 
that 2-formylpyridine TSC possesses antileukaemic activity in mice bearing 
leukaemic cells (Brockman, Thomson, J, & Skipper, 1956). Following this initial 
report, a large series of TSCs derived from 2-formylpyridines, isoquinoline-1 
carboxaldehydes, and 2-acetylpyridine were synthesised and their in vivo antitumour 
activity were evaluated. Among the derivatives, 5-hydroxypyridine TSC (15), which 
showed significant antitumour activity has been selected for clinical phase I 
evaluation (Agrawal & Sartorelli, 1978; Scovill, Klayman, & Franchino, 1982).  
 
N
OH
N
NH NH
NH2
S
 
 
15 
 
In 2001, Easmon and co-workers reported a series of thiosemicarbazones bearing a 
N-azabicyclo[3.2.2]nonane moiety derived from 3-acylpyridazines (16), 4-
acetylpyrimidines (17), and 2-acetylpyrazines (18) exhibits cytotoxic activity against 
human acute lymphoblastic leukaemia CCRF-CEM cells (IC50 = 0.05 – 0.77 μM) 
and colon adenocarcinoma HT-29 cells (IC50 = 0.011 – 2.22 μM) (Easmon et al., 
2001).  
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Very recently, Hu and co-workers reported synthesis of ten liquiritigenin 
thiosemicarbazone derivatives (19) and their antitumour activities against five cell 
lines (K562, DU-145, SGC-7901, HCT-116, Hela). Most of the prepared compounds 
displayed the selective cytotoxicity toward K562 and DU-145 cell lines. Based on 
the structure-activity relationship (SAR) analysis, it has been concluded that the 
introduction of thiosemicarbazone at 4-position in liquiritigenin is associated with 
enhanced cytotoxic activity (Hu, Yang, Pan, Xu, & Ren, 2010).  
 
 
 
16 17 
18 
    
14 
 
N
NH
RS
OH
R = NCH
2
CH
2
CH
3
R = NCH(CH
3
)
2
R = NCH
2
CH
2
CH
2
CH
3
R = NC(CH
3
)
3
R = N(CH
2
CH
2
CH
3
)
2
R = 
R = 
R = 
R = 
R = N
N NH
N N CH3
N NH
N O
19 
 
To date, the most significant progress in the treatment of cancer has been made with 
3-aminopyridine-2-carboxaldehyde TSC (20) which has undergone phase II clinical 
trials. The biological activity of organometallic derived TSC and their metal 
complexes remains unexplored and this work would in some ways contribute to its 
development.  
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1.4 Objectives 
 
The objectives of this study were: 
1. To synthesise and characterise a series of zinc(II) 
ferrocenylthiosemicarbazone complexes derived from thiosemicarbazide, 4-methyl-
3-thiosemicarbazide, 4-ethyl-3-thiosemicarbazide and 4-phenyl-3-thiosemicarbazide. 
2. To study DNA binding behaviour and nuclease activity of the zinc(II) 
complexes.  
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2 EXPERIMENTAL 
 
2.1  Materials and measurements 
All the reagents and chemicals were obtained from commercial sources 
(Acros Chemicals, Aldrich) and used as such. Supercoiled (SC) pBR 322 DNA and 
loading dye were purchased from Fermentas. Ultrapure water (18.2 MΩ.cm) was 
obtained from a Barnstead water purification unit. Calf thymus (CT) DNA, agarose 
(molecular biology grade) and ethidium bromide (EB) were from Sigma. The 
elemental analysis was carried out using Perkin–Elmer 2400 series-11 CHN/O 
analyser. The infrared, electronic and fluorescence spectra were recorded on Perkin–
Elmer 2000, Perkin Elmer-Lambda 35 and Jasco FP-750 spectrophotometers 
respectively. Molar conductivity measurements were made using a Eutech Con 510 
conductivity meter. Cyclic voltammetric measurements were done on a BAS-Epsilon 
electrochemical system using a three electrode set-up comprising of a platinum disc 
working, platinum wire auxiliary and an Ag/AgCl reference electrode. 
Tetrabutylammonium hexafluorophosphate (TBAPF6) (0.1 M) was used as a 
supporting electrolyte in acetonitrile. 
 
2.2  X-ray crystallography 
Determination of cell constant and data collection were carried out at 
100.0(1) K using the Oxford Cryosystem Cobra low-temperature attachment with 
Mo-Kα radiation (λ = 0.71073 Å) on Bruker SMART APEXII CCD area-detector 
diffractometer equipped with a graphite monochromator. The data were reduced 
using SAINT. A semi-empirical absorption correction was applied to the data using 
SADABS. The structures were solved by direct methods and refined against F
2
 by 
full-matrix least-squares using SHELXTL. All hydrogen atoms were positioned 
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geometrically and were refined using a riding model whereas non-hydrogen atoms 
were refined anisotropically.  
 
2.3  DNA binding 
2.3.1  Preparation of reagents 
To prepare Tris HCl (5 mM Tris-HCl, 50 mM NaCl, pH 7.1) buffer for 
titrations, 0.0785 g (0.5 mmol) of Tris HCl was dissolved in 85 mL of ultra pure 
water with constant stirring. To this solution (0.2922 g, 5 mmol) of NaCl salt was 
added and the solution was stirred to have complete dissolution. The pH of the buffer 
solution was then adjusted to pH 7.1 by adding small aliquots of 1M HCl. The final 
volume of the solution was adjusted to 100 mL using ultra pure water. The final pH 
of the solution was then confirmed with the pH meter. The Tris HCl solution was 
prepared fresh before each experiment and not used for more than 2 − 3 days. The 
pH of the Tris HCl buffer solution was constantly verified before each titration. To 
prepare CT DNA solution, approximately 0.05 g of CT DNA was dissolved in 50 
mL Tris HCl buffer and constantly stirred overnight to ensure complete dissolution. 
The resulting solution was then filtered through a 0.2 μm nylon filter. Precautions 
were taken to avoid contamination of the DNA by other biological materials. 
Solutions of CT DNA were prepared fresh before each experiment and not used 
more than 2 days. The concentration of DNA solution expressed in moles was 
determined by UV-visible spectrophotometer. The absorbance of the resulting 
filtered DNA solution was measured against Tris HCl buffer as blank in the range of 
200 − 800 nm. When DNA is isolated from organisms, usually there remains protein 
present in the DNA solution; protein is tightly bound to DNA and complete removal 
of protein is not always possible. To calculate the concentration and purity of the 
DNA solution, the absorbance of UV light is measured in a spectrophotometer. Both 
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protein and DNA absorb UV light, except they have different absorbance curves. 
The peak of light absorption for DNA is at 260 nm and for protein at 280 nm. The 
solution of CT DNA in the buffer gave a ratio of UV absorbance at 260 and 280 nm 
of 1.8 − 1.9 : 1 for all the stock solutions of DNA prepared indicating that the DNA 
was sufficiently free of protein (Reichmann, Rice, Thomas, & Doty, 1954). 
Therefore no further purification was attempted. The DNA concentration per 
nucleotide was determined using the molar absorption coefficient of 6600 M
-1
 cm
-1
 
at 260 nm. 
 
2.3.2  Absorption spectral titration 
For absorption titration, the spectrum was recorded in the range of 200 – 800 
nm. The UV-vis scan rate was set to 600 nm/min, and the data interval as 1 nm. The 
titrations were performed in quartz cuvettes with 10 mm pathlength. The absorption 
titrations of ligands or metal complexes were performed using a fixed concentration 
of compound to which increments of the DNA solution were added. The sample 
cuvette was filled with 3 mL of the ligand or metal complex solution and the 
reference cuvette with 3 mL of Tris buffer. Both the cuvettes were left in the 
spectrophotometer and an equal amount of DNA solution was added to both the 
compound solution and the reference solution. The solutions were allowed to 
equilibrate for 10 minutes before the next addition. The sequence of addition of 
DNA, equilibration for 10 minutes and measurement of the spectra were repeated for 
6 additions. 
 
2.3.3  Fluorescence spectral titration 
For fluorescence titration, all the samples were excited at their respective 
absorption maxima (λmax) and the emission were observed at ca. 410 nm. The 
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excitation slit width was set as 5 nm while the emission slit width was set to 10 nm. 
The average time interval was set to 1 second and the data interval to 2.00 nm 
yielding a scan rate of 120 nm/s. The titrations of ligands or metal complexes were 
performed using a fixed concentration of compound to which increments of the DNA 
solution were added. The sample quvette was filled with 3 mL of the ligand or metal 
complex solution and 50 μl of DNA solution was added. The solution was allowed to 
equilibrate for 2 minutes before next addition. The sequence of addition of DNA, 
equilibration for 2 minutes and measurement of the spectra were repeated for 5 
additions. 
 
2.3.4  Viscosity measurements 
Viscosity measurements were made using Cannon Manning Semi-Micro 
viscometer. The viscometer was thermostated at 30 
o
C in a constant temperature 
bath. The flow time of a series of DNA solutions (40 μM) containing varying 
concentrations of metal complex were measured manually using a digital stopwatch. 
The flow time of the Tris HCl buffer also measured. Data were presented as (η/η0)
1/3
 
versus the ratio of the concentration of the complex and DNA, where η is the 
viscosity of DNA in the presence of complex and η0 is the viscosity of DNA alone. 
Viscosity values were calculated from the observed flowing time of DNA-containing 
solutions (t) corrected for that of the buffer alone (t0), η = (t - t0)/t0.  
 
2.4  DNA cleavage experiments 
The cleavage of supercoiled pBR322 DNA (0.5 μg/μl) was studied by 
agarose gel electrophoresis. To prepare agarose gel, 0.4 g of agarose was added to 40 
mL of TAE buffer and the mixture was heated in a microwave oven to boil. The 
solution obtained was cooled in water bath to 60 
o
C before being poured into a gel 
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mould. A gel comb was placed at one end of the mould. After 30 minutes, the 
solution transformed into a gel and the comb was removed. In cleavage reactions, 
supercoiled DNA was treated with solutions of metal complexes (concentrations 
given in the figure captions). The samples were incubated at 37 
o
C
 
for 2 h, under an 
argon atmosphere in the dark (i.e., in apparatus that was wrapped in an aluminium 
foil). Each sample was added loading dye and the solution was loaded on agarose gel 
with a running time of 1 h at a constant voltage of 50 V. The resultant DNA bands 
after the electrophoresis step were stained with ethidium bromide before being 
photographed under UV light.  
 
2.5 Preparation of ferrocenylthiosemicarbazone ligands 
Ferrocene-1-carbaldehyde thiosemicarbazone, HFTSC (I) 
To a stirred suspension of thiosemicarbazide (0.213 g, 2.336 mmol) in water 
(40 mL) a few drops of 36% hydrochloric acid (wt% in H2O) and 
ferrocenecarboxaldehyde (0.499 g, 2.336 mmol) were added. The resulting mixture 
was stirred for 4 h at room temperature. The precipitate formed was filtered off, 
washed with water and dried in vacuum over silica gel to yield an orange powder 
(0.23 g, 80%). Mp: 175 – 177 oC. Calculated for C12H13N3SFe: C, 50.19; H, 4.56; N, 
14.63%. Found: C, 50.16; H, 4.73; N, 14.44. IR data (KBr, cm
-1
): 3430, 3279, 3144, 
ν(N–H); 1600, ν(C=N); 840, ν(C=S). UV-vis in aqueous DMF (10% DMF) [λmax, 
nm (ε, M-1 cm-1)]: 265 (11322), 306 (22882), 454 (1038). 
 
All other thiosemicarbazone ligands were made similarly using the appropriate 
thiosemicarbazides. The ligands were obtained as orange (HFMTSC, HFETSC) or 
red (HFPTSC) powder. 
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Ferrocene-1-carbaldehyde 4-methylthiosemicarbazone, HFMTSC (II) 
This compound was made from 4-methyl-3-thiosemicarbazide (0.246 g, 
2.336 mmol). Yield: 0.256 g, 85%. Mp: 135 – 136 oC. Calculated for C13H15N3SFe: 
C, 52.14; H, 5.20; N, 13.95%. Found: C, 52.31; H, 5.29; N, 13.72. IR data (KBr, cm
-
1
): 3370, 3300, 3255, 3136, ν(N–H); 1602, ν(C=N); 850, ν(C=S). UV-vis in aqueous 
DMF (10% DMF) [λmax, nm (ε, M
-1
 cm
-1
)]: 263 (12235), 308 (23489), 454 (773). 
 
Ferrocene-1-carbaldehyde 4-ethylthiosemicarbazone, HFETSC (III) 
This compound was made from 4-ethyl-3-thiosemicarbazide (0.278 g, 
2.336 mmol). Yield: 0.293 g, 93%. Mp: 144 – 146 oC. Calculated for C14H17N3SFe: 
C, 53.35; H, 5.44; N, 13.33%. Found: C, 53.67; H, 5.71; N, 13.12. IR data (KBr, cm
-
1
): 3363, 3150, ν(N–H); 1603, ν(C=N); 827, ν(C=S). UV-vis in aqueous DMF (10% 
DMF) [λmax, nm (ε, M
-1
 cm
-1
)]: 263 (14764), 308 (26571), 460 (1700). 
 
Ferrocene-1-carbaldehyde 4-phenylthiosemicarbazone, HFPTSC (IV) 
This compound was made from 4-phenyl-3-thiosemicarbazide (0.390 g, 
2.336 mmol). Yield: 0.331 g, 91%. Mp: 190 – 192 oC. Calculated for C18H17N3SFe: 
C, 59.52; H, 4.72; N, 11.57%. Found: C, 59.32; H, 4.60; N, 11.57. IR data (KBr, cm
-
1
): 3345, 3314, 3124, ν(N–H); 1601, ν(C=N); 830, ν(C=S). UV-vis in aqueous DMF 
(10% DMF) [λmax, nm (ε, M
-1
 cm
-1
)]: 266 (15151), 312 (21977), 460 (1603). 
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2.6 Preparation of zinc complexes 
 
Bis(ferrocenecarbaldehyde thiosemicarbazonato)zinc(II), Zn(FTSC)2 (V) 
Zn(CH3COO
-
)2.2H2O (0.21 g,1 mmol) dissolved in methanol (60 mL) was 
added dropwise at room temperature to a mixture of HFTSC (0.29 g, 1 mmol) and 
KOH (0.12 g, 2 mmol) in methanol (15 mL). Amorphous orange solids separated out 
immediately. The suspension was stirred under reflux for 4 h and filtered. Allowing 
the filtrate to evaporate slowly at room temperature gave the product as brown 
crystals (0.252 g, 79%). These crystals were suitable for X-ray crystallography. Mp: 
>230 
o
C (dec). Calculated for C24H24N6S2Fe2Zn: C, 45.20; H, 3.79; N, 13.18%. 
Found: C, 45.08; H, 3.48; N, 12.79. IR data (KBr, cm
-1
): 3453, 3344, ν(N–H); 1596, 
ν(C=N); 834, ν(C−S). UV-vis in aqueous DMF (10% DMF) [λmax, nm (ε, M
-1
 cm
-1
)]: 
265 (23734), 306 (44613), 460 (2427). Molar conductivity (10
-3
 M, DMF): 2.3. 
 
All other complexes were made similarly using the appropriate thiosemicarbazone 
ligands. The complexes were obtained as brown crystals (diffraction grade). 
 
Bis(ferrocenecarbaldehyde 4-methylthiosemicarbazonato)zinc(II) Monomethanol, 
Zn(FMTSC)∙CH3OH (VI) 
This compound was made from HFMTSC (0.30 g, 1 mmol). Yield: 0.29 g, 
83%. Mp: >230 
o
C (dec). Calculated for C27H32Fe2N6OS2Zn: C, 46.48; H, 4.62; N, 
12.04%. Found: C, 46.10; H, 4.58; N, 12.36. IR data (KBr, cm
-1
): 3368, ν(N–H); 
1601, ν(C=N); 835, ν(C−S). UV-vis in aqueous DMF (10% DMF) [λmax, nm (ε, M
-1
 
cm
-1
)]: 262 (28785), 308 (53067), 458 (2714). Molar conductivity (10
-3
 M, DMF): 
2.4 S cm
2
 mol
-1
. 
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Bis(ferrocenecarbaldehyde 4-ethylthiosemicarbazonato)zinc(II), Zn(FETSC) (VII)  
This compound was made from HFETSC (0.32 g, 1 mmol). Yield: 0.281 g, 
81%. Mp: >230 
o
C (dec). Calculated for C28H32 N6 S2 Fe2 Zn: C, 48.47; H, 4.65; N, 
12.11%. Found: C, 48.12; H, 4.29; N, 11.71. IR data (KBr, cm
-1
): 3339, ν(N–H); 
1601, ν(C=N); 820, ν(C−S). UV-vis in aqueous DMF (10% DMF) [λmax, nm (ε, M
-1
 
cm
-1
)]: 262 (25309), 308 (44736), 457 (3068). Molar conductivity (10
-3
 M, DMF): 
3.3 S cm
2
 mol
-1
. 
 
Bis(ferrocenecarbaldehyde 4-phenylthiosemicarbazonato)zinc(II) Monohydrate, 
Zn(FPTSC)∙H2O (VIII)  
This compound was made from HFPTSC (0.36 g, 1 mmol). Yield: 0.311 g, 
77%. Mp: >230 
o
C (dec). Calculated for C36H34Fe2N6OS2Zn: C, 53.52; H, 4.24; N, 
10.40%. Found: C, 53.51; H, 4.41; N, 10.01. IR data (KBr, cm
-1
): 3319, ν(N–H); 
1601, ν(C=N); 828, ν(C−S). UV-vis in aqueous DMF (10% DMF) [λmax, nm (ε, M
-1
 
cm
-1
)]: 266 (28766), 320 (39530), 446 (1423). Molar conductivity (10
-3
 M, DMF): 
2.1 S cm
2
 mol
-1
. 
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3 RESULTS AND DISCUSSION  
3.1 Synthesis and General Aspects 
The ferrocenylthiosemicarbazone ligands HFTSC (I), HFMTSC (II), 
HFETSC (III) and HFPTSC (IV) were prepared following published procedure 
(Casas et al., 2004), by a reaction of ferrocenecarboxaldehyde with corresponding 
thiosemicarbazide in the presence of HCl as a catalyst at room temperature (Scheme 
1.2). They are stable in solid state, but start to decompose in solution (darkening) if 
left for 3 days under normal laboratory conditions.  
R
S
NH NH
NH2 H2
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Scheme 3.1: General synthesis of ferrocenylthiosemicarbazone ligands. 
 
  
Fe
O
O
O
O
Zn
N
R
S
NHNH
Fe
Fe
N
S
R
NH
N
Zn
N
S
N
NH
R
stir, 4 h
R = H, V; CH
3
, VI; C
2
H
5
, VII; C
6
H
5
, VII
Scheme 3.2: General synthesis of zinc complexes. 
 
The new zinc complexes Zn(FTSC)2 (V), Zn(FMTSC)2∙CH3OH (VI), 
Zn(FETSC)2 (VII) and Zn(FPTSC)2∙H2O (VIII) have been isolated from 
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methanolic solutions containing dihydrated zinc(II) acetate as the starting material 
(Scheme 3.2). All the complexes were obtained in good yields (>75%) and 
characterised by elemental analysis, FT-IR, UV-vis and cyclic voltammetry. They 
are soluble in acetone, acetonitrile (except complex V), DMF and DMSO and did not 
exhibit decomposition in 10% aqueous DMF after 3 h incubation at 37 
o
C 
(monitored by UV-vis spectroscopy). The molar conductivity values were in the 
range 2.3 to 3.3 S cm
-2 
mol
-1
 (Table 3.1)
 
indicating that these complexes are non-
electrolytes (Geary, 1971). The electronic spectra of the complexes in aqueous DMF 
showed a ferrocene-centred band at ca. 455 nm and, the remaining ligand-centred 
bands in the UV region. In the infrared spectra of the complexes, the number of 
bands corresponding to ν(N−H) vibrations has decreased compared to those of the 
free ligands owing to deprotonation (Calatayud, LÃ³pez-Torres, & Mendiola, 2007). 
The energy of these bands is shifted to higher energy relative to those in the spectra 
of the free ligands. However, the shifts (either to lower energy or higher energy) 
observed in the bands assigned to ν(CN) and ν(CS) are found to be insignificant. The 
structures of the complexes have been revealed by single crystal X-ray 
crystallography. 
 
Table 3.1: Selected physicochemical data for the zinc complexes. 
  
IR
a
/cm
-1
  
[ν(CN], [νCS] 
Visible spectra band
b 
λmax (ԑ/M
-1
 cm
-1
) 
Molar conductance
 
ɅM
c
/ S cm
-2 
mol
-1
 
V 1596, 834 460 (2427) 2.3 
VI 1601, 835 458 (2714) 2.4 
VII 1601, 820 457 (3068) 3.3 
VIII 1601, 828 446 (1423) 2.1 
a
 In KBr 
b 
In aqueous DMF (9:1 v/v) 
c 
Molar conductivity in DMF 
 
 
